<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>pediatrics</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://yorks0n.github.io/TRxiv2" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/TRxiv2/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>pediatrics | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="The fungal intestinal microbiota predict the development of bronchopulmonary dysplasia in very low birthweight newborns
Authors: Willis, K. A.; Silverberg, M.; Martin, I.; Abdelgawad, A.; Karabayir, I.; Halloran, B. A.; Myers, E. D.; Desai, J. P.; White, C. T.; Lal, C. V.; Ambalavanan, N.; Peters, B. M.; Jain, V. G.; Akbilgic, O.; Tipton, L.; Jilling, T.; Cormier, S. A.; Pierre, J. F.; Talati, A. J.
Score: 9.7, Published: 2023-06-22 DOI: 10.">
<meta name="author" content="">
<link rel="canonical" href="https://yorks0n.github.io/TRxiv2/posts/pediatrics/">
<link crossorigin="anonymous" href="/TRxiv2/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/TRxiv2/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://yorks0n.github.io/TRxiv2/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://yorks0n.github.io/TRxiv2/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://yorks0n.github.io/TRxiv2/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://yorks0n.github.io/TRxiv2/apple-touch-icon.png">
<link rel="mask-icon" href="https://yorks0n.github.io/TRxiv2/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="pediatrics" />
<meta property="og:description" content="The fungal intestinal microbiota predict the development of bronchopulmonary dysplasia in very low birthweight newborns
Authors: Willis, K. A.; Silverberg, M.; Martin, I.; Abdelgawad, A.; Karabayir, I.; Halloran, B. A.; Myers, E. D.; Desai, J. P.; White, C. T.; Lal, C. V.; Ambalavanan, N.; Peters, B. M.; Jain, V. G.; Akbilgic, O.; Tipton, L.; Jilling, T.; Cormier, S. A.; Pierre, J. F.; Talati, A. J.
Score: 9.7, Published: 2023-06-22 DOI: 10." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://yorks0n.github.io/TRxiv2/posts/pediatrics/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-06-28T09:51:07+00:00" />
<meta property="article:modified_time" content="2023-06-28T09:51:07+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="pediatrics"/>
<meta name="twitter:description" content="The fungal intestinal microbiota predict the development of bronchopulmonary dysplasia in very low birthweight newborns
Authors: Willis, K. A.; Silverberg, M.; Martin, I.; Abdelgawad, A.; Karabayir, I.; Halloran, B. A.; Myers, E. D.; Desai, J. P.; White, C. T.; Lal, C. V.; Ambalavanan, N.; Peters, B. M.; Jain, V. G.; Akbilgic, O.; Tipton, L.; Jilling, T.; Cormier, S. A.; Pierre, J. F.; Talati, A. J.
Score: 9.7, Published: 2023-06-22 DOI: 10."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://yorks0n.github.io/TRxiv2/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "pediatrics",
      "item": "https://yorks0n.github.io/TRxiv2/posts/pediatrics/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "pediatrics",
  "name": "pediatrics",
  "description": "The fungal intestinal microbiota predict the development of bronchopulmonary dysplasia in very low birthweight newborns\nAuthors: Willis, K. A.; Silverberg, M.; Martin, I.; Abdelgawad, A.; Karabayir, I.; Halloran, B. A.; Myers, E. D.; Desai, J. P.; White, C. T.; Lal, C. V.; Ambalavanan, N.; Peters, B. M.; Jain, V. G.; Akbilgic, O.; Tipton, L.; Jilling, T.; Cormier, S. A.; Pierre, J. F.; Talati, A. J.\nScore: 9.7, Published: 2023-06-22 DOI: 10.",
  "keywords": [
    
  ],
  "articleBody": " The fungal intestinal microbiota predict the development of bronchopulmonary dysplasia in very low birthweight newborns\nAuthors: Willis, K. A.; Silverberg, M.; Martin, I.; Abdelgawad, A.; Karabayir, I.; Halloran, B. A.; Myers, E. D.; Desai, J. P.; White, C. T.; Lal, C. V.; Ambalavanan, N.; Peters, B. M.; Jain, V. G.; Akbilgic, O.; Tipton, L.; Jilling, T.; Cormier, S. A.; Pierre, J. F.; Talati, A. J.\nScore: 9.7, Published: 2023-06-22 DOI: 10.1101/2023.05.29.23290625\nRationaleBronchopulmonary dysplasia (BPD) is the most common morbidity affecting very preterm infants. Gut microbial communities contribute to multiple lung diseases, and alterations of the gut microbiome may be a factor in BPD pathogenesis. ObjectiveTo determine if features of the multikingdom gut microbiome predict the development of BPD in very low birthweight newborns. MethodsWe performed a prospective, observational cohort study comparing the multikingdom fecal microbiota of 147 preterm infants with BPD or post-prematurity respiratory disease (PPRD) by sequencing bacterial 16S and fungal ITS2 ribosomal RNA gene. To address the potential causative relationship between gut dysbiosis and BPD, we used fecal microbiota transplant in an antibiotic-pseudohumanized mouse model. Comparisons were made using RNA sequencing, quantitative confocal microscopy, lung morphometry, and oscillometry. Measurements and Main ResultsWe analyzed 100 fecal microbiome samples collected during the second week of life. Infants who later developed BPD showed an obvious fungal dysbiosis as compared to infants with PPRD (P = 0.0209). Instead of fungal communities dominated by Candida and Saccharomyces, the microbiota of infants who developed BPD were characterized by the abundance of Aureobasidium and a greater diversity of rarer fungi in less interconnected community architectures. On successful colonization, the gut microbiota from infants with BPD augmented lung injury in the offspring of recipient animals. We identified alterations in the murine lung and intestinal microbiomes and transcriptional alterations associated with augmented lung injury. ConclusionsThe gut fungal microbiome of infants who will develop BPD is dysbiotic and may contribute to disease pathogenesis. Trial RegistrationNCT03229967.\nA distinct cross-reactive autoimmune response in multisystem inflammatory syndrome in children (MIS-C)\nAuthors: Bodansky, A.; Sabatino, J. J.; Vazquez, S.; Chou, J.; Novak, T.; Moffitt, K. L.; Miller, H.; Kung, A.; Rackaityte, E.; Zamecnik, C. R.; Rajan, J. V.; Kortbawi, H.; Mandel-Brehm, C.; Mitchell, A.; Wang, C.-Y.; Saxena, A.; Zorn, K.; Yu, D. J. L.; Asaki, J.; Pluvinage, J. V.; Wilson, M. R.; Loftis, L. L.; Hobbs, C. V.; Tarquinio, K. M.; Kong, M.; Fitzgerald, J. C.; Espinal, P. S.; Walker, T. C.; Schwartz, S. P.; Crandall, H.; Irby, K.; Staat, M. A.; Rowan, C. M.; Schuster, J. E.; Halasa, N. B.; Gertz, S. J.; Mack, E. H.; Maddux, A. B.; Cvijanovich, N. Z.; Zinter, M. S.; Zambrano, L. D.; Campbell,\nScore: 124.7, Published: 2023-05-30 DOI: 10.1101/2023.05.26.23290373\nMultisystem inflammatory syndrome in children (MIS-C) is a severe, post-infectious sequela of SARS-CoV-2 infection, yet the pathophysiological mechanism connecting the infection to the broad inflammatory syndrome remains unknown. Here we leveraged a large set of MIS-C patient samples (n=199) to identify a distinct set of host proteins that are differentially targeted by patient autoantibodies relative to matched controls. We identified an autoreactive epitope within SNX8, a protein expressed primarily in immune cells which regulates an antiviral pathway associated with MIS-C pathogenesis. In parallel, we also probed the SARS-CoV-2 proteome-wide MIS-C patient antibody response and found it to be differentially reactive to a distinct domain of the SARS-CoV-2 nucleocapsid (N) protein relative to controls. This viral N region and the mapped SNX8 epitope bear remarkable biochemical similarity. Furthermore, we find that many children with anti-SNX8 autoantibodies also have T-cells cross-reactive to both SNX8 and this distinct domain of the SARS-CoV-2 N protein. Together, these findings suggest that MIS-C patients develop a distinct immune response against the SARS-CoV-2 N protein that is associated with cross reactivity to the self-protein SNX8, demonstrating a link from the infection to the inflammatory syndrome.\nReal-world Effectiveness of BNT162b2 in Children and Adolescents\nAuthors: Wu, Q.; Tong, J.; Zhang, B.; Zhang, D.; Xu, J.; Shen, Y.; Li, L.; Bailey, C.; Bian, J.; Christakis, D.; Fitzgerald, M. L.; Hirabayashi, K.; Jhaveri, R.; Khaitan, A.; Lyu, T.; Rao, S.; Razzaghi, H.; Schwenk, H.; Wang, F.; Gage Witvliet, M.; Tchetgen Tchetgen, E. J.; Morris, J. S.; Forrest, C. B.; Chen, Y.\nScore: 1.0, Published: 2023-06-21 DOI: 10.1101/2023.06.16.23291515\nBACKGROUNDThe current understanding of the long-term effectiveness of the BNT162b2 vaccine for a range of outcomes across diverse U.S. pediatric populations is limited. In this study, we assessed the effectiveness of BNT162b2 against various strains of the SARS-CoV-2 virus using data from a national collaboration of pediatric health systems (PEDSnet). METHODSWe emulated three target trials to assess the real-world effectiveness of BNT162b2: adolescents aged 12 to 20 years during the Delta variant period (Target trial 1), children aged 5 to 11 years (Target trial 2) and adolescents aged 12 to 20 years during the Omicron variant period (Target trial 3). The outcomes included documented infection, COVID-19 illness severity, admission to an intensive care unit (ICU), and two cardiac-related outcomes, myocarditis and pericarditis. In the U.S., immunization records are often captured and stored across multiple disconnected sources, resulting in incomplete vaccination records in patients electronic health records (EHR). We implemented a novel trial emulation pipeline accounting for possible misclassification bias in vaccine documentation in EHRs. The effectiveness of the BNT162b2 vaccine was estimated from the Poisson regression model with confounders balanced via propensity score stratification. RESULTSDuring the Delta period, the BNT162b2 vaccine demonstrated an overall effectiveness 98.4% (95% CI, 98.1 to 98.7) against documented infection among adolescents, with no significant waning after receipt of the first dose. During the Omicron period, the overall effectiveness was estimated to be 74.3% (95% CI, 72.2 to 76.2) in preventing documented infection among children, which was higher against moderate or severe COVID-19 (75.5%; 95% CI, 69.0 to 81.0) and ICU admission with COVID-19 (84.9%; 95% CI, 64.8 to 93.5). In the adolescent population, the overall effectiveness against documented Omicron infection was 85.5% (95% CI, 83.8 to 87.1), with effectiveness of 84.8% (95% CI, 77.3 to 89.9) against moderate or severe COVID-19, and 91.5% (95% CI, 69.5 to 97.6) against ICU admission with COVID-19. The effectiveness of the BNT162b2 vaccine against the Omicron variant declined after 4 months following the first dose and then stabilized with higher levels of uncertainty. Across all three cohorts, the risk of cardiac outcomes was approximately 65% to 85% lower in the vaccinated group than that of the unvaccinated group accounting for possible misclassification bias. CONCLUSIONSThis study suggests BNT162b2 was effective among children and adolescents in Delta and Omicron periods for a range of COVID-19-related outcomes and is associated with a lower risk for cardiac complications. Waning effectiveness over time suggests that revaccination may be needed in the future.\n",
  "wordCount" : "1109",
  "inLanguage": "en",
  "datePublished": "2023-06-28T09:51:07Z",
  "dateModified": "2023-06-28T09:51:07Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://yorks0n.github.io/TRxiv2/posts/pediatrics/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://yorks0n.github.io/TRxiv2/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://yorks0n.github.io/TRxiv2" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      pediatrics
    </h1>
    <div class="post-meta"><span>updated on June 28, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.05.29.23290625">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.05.29.23290625" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.05.29.23290625">
        <p class="paperTitle">The fungal intestinal microbiota predict the development of bronchopulmonary dysplasia in very low birthweight newborns</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.05.29.23290625" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.05.29.23290625" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Willis, K. A.; Silverberg, M.; Martin, I.; Abdelgawad, A.; Karabayir, I.; Halloran, B. A.; Myers, E. D.; Desai, J. P.; White, C. T.; Lal, C. V.; Ambalavanan, N.; Peters, B. M.; Jain, V. G.; Akbilgic, O.; Tipton, L.; Jilling, T.; Cormier, S. A.; Pierre, J. F.; Talati, A. J.</p>
        <p class="info">Score: 9.7, Published: 2023-06-22 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.05.29.23290625' target='https://doi.org/10.1101/2023.05.29.23290625'> 10.1101/2023.05.29.23290625</a></p>
        <p class="abstract">RationaleBronchopulmonary dysplasia (BPD) is the most common morbidity affecting very preterm infants. Gut microbial communities contribute to multiple lung diseases, and alterations of the gut microbiome may be a factor in BPD pathogenesis.

ObjectiveTo determine if features of the multikingdom gut microbiome predict the development of BPD in very low birthweight newborns.

MethodsWe performed a prospective, observational cohort study comparing the multikingdom fecal microbiota of 147 preterm infants with BPD or post-prematurity respiratory disease (PPRD) by sequencing bacterial 16S and fungal ITS2 ribosomal RNA gene. To address the potential causative relationship between gut dysbiosis and BPD, we used fecal microbiota transplant in an antibiotic-pseudohumanized mouse model. Comparisons were made using RNA sequencing, quantitative confocal microscopy, lung morphometry, and oscillometry.

Measurements and Main ResultsWe analyzed 100 fecal microbiome samples collected during the second week of life. Infants who later developed BPD showed an obvious fungal dysbiosis as compared to infants with PPRD (P = 0.0209). Instead of fungal communities dominated by Candida and Saccharomyces, the microbiota of infants who developed BPD were characterized by the abundance of Aureobasidium and a greater diversity of rarer fungi in less interconnected community architectures. On successful colonization, the gut microbiota from infants with BPD augmented lung injury in the offspring of recipient animals. We identified alterations in the murine lung and intestinal microbiomes and transcriptional alterations associated with augmented lung injury.

ConclusionsThe gut fungal microbiome of infants who will develop BPD is dysbiotic and may contribute to disease pathogenesis.

Trial RegistrationNCT03229967.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.05.26.23290373">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.05.26.23290373" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.05.26.23290373">
        <p class="paperTitle">A distinct cross-reactive autoimmune response in multisystem inflammatory syndrome in children (MIS-C)</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.05.26.23290373" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.05.26.23290373" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Bodansky, A.; Sabatino, J. J.; Vazquez, S.; Chou, J.; Novak, T.; Moffitt, K. L.; Miller, H.; Kung, A.; Rackaityte, E.; Zamecnik, C. R.; Rajan, J. V.; Kortbawi, H.; Mandel-Brehm, C.; Mitchell, A.; Wang, C.-Y.; Saxena, A.; Zorn, K.; Yu, D. J. L.; Asaki, J.; Pluvinage, J. V.; Wilson, M. R.; Loftis, L. L.; Hobbs, C. V.; Tarquinio, K. M.; Kong, M.; Fitzgerald, J. C.; Espinal, P. S.; Walker, T. C.; Schwartz, S. P.; Crandall, H.; Irby, K.; Staat, M. A.; Rowan, C. M.; Schuster, J. E.; Halasa, N. B.; Gertz, S. J.; Mack, E. H.; Maddux, A. B.; Cvijanovich, N. Z.; Zinter, M. S.; Zambrano, L. D.; Campbell,</p>
        <p class="info">Score: 124.7, Published: 2023-05-30 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.05.26.23290373' target='https://doi.org/10.1101/2023.05.26.23290373'> 10.1101/2023.05.26.23290373</a></p>
        <p class="abstract">Multisystem inflammatory syndrome in children (MIS-C) is a severe, post-infectious sequela of SARS-CoV-2 infection, yet the pathophysiological mechanism connecting the infection to the broad inflammatory syndrome remains unknown. Here we leveraged a large set of MIS-C patient samples (n=199) to identify a distinct set of host proteins that are differentially targeted by patient autoantibodies relative to matched controls. We identified an autoreactive epitope within SNX8, a protein expressed primarily in immune cells which regulates an antiviral pathway associated with MIS-C pathogenesis. In parallel, we also probed the SARS-CoV-2 proteome-wide MIS-C patient antibody response and found it to be differentially reactive to a distinct domain of the SARS-CoV-2 nucleocapsid (N) protein relative to controls. This viral N region and the mapped SNX8 epitope bear remarkable biochemical similarity. Furthermore, we find that many children with anti-SNX8 autoantibodies also have T-cells cross-reactive to both SNX8 and this distinct domain of the SARS-CoV-2 N protein. Together, these findings suggest that MIS-C patients develop a distinct immune response against the SARS-CoV-2 N protein that is associated with cross reactivity to the self-protein SNX8, demonstrating a link from the infection to the inflammatory syndrome.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.06.16.23291515">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.06.16.23291515" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.06.16.23291515">
        <p class="paperTitle">Real-world Effectiveness of BNT162b2 in Children and Adolescents</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.06.16.23291515" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.06.16.23291515" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Wu, Q.; Tong, J.; Zhang, B.; Zhang, D.; Xu, J.; Shen, Y.; Li, L.; Bailey, C.; Bian, J.; Christakis, D.; Fitzgerald, M. L.; Hirabayashi, K.; Jhaveri, R.; Khaitan, A.; Lyu, T.; Rao, S.; Razzaghi, H.; Schwenk, H.; Wang, F.; Gage Witvliet, M.; Tchetgen Tchetgen, E. J.; Morris, J. S.; Forrest, C. B.; Chen, Y.</p>
        <p class="info">Score: 1.0, Published: 2023-06-21 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.06.16.23291515' target='https://doi.org/10.1101/2023.06.16.23291515'> 10.1101/2023.06.16.23291515</a></p>
        <p class="abstract">BACKGROUNDThe current understanding of the long-term effectiveness of the BNT162b2 vaccine for a range of outcomes across diverse U.S. pediatric populations is limited. In this study, we assessed the effectiveness of BNT162b2 against various strains of the SARS-CoV-2 virus using data from a national collaboration of pediatric health systems (PEDSnet).

METHODSWe emulated three target trials to assess the real-world effectiveness of BNT162b2: adolescents aged 12 to 20 years during the Delta variant period (Target trial 1), children aged 5 to 11 years (Target trial 2) and adolescents aged 12 to 20 years during the Omicron variant period (Target trial 3). The outcomes included documented infection, COVID-19 illness severity, admission to an intensive care unit (ICU), and two cardiac-related outcomes, myocarditis and pericarditis. In the U.S., immunization records are often captured and stored across multiple disconnected sources, resulting in incomplete vaccination records in patients electronic health records (EHR). We implemented a novel trial emulation pipeline accounting for possible misclassification bias in vaccine documentation in EHRs. The effectiveness of the BNT162b2 vaccine was estimated from the Poisson regression model with confounders balanced via propensity score stratification.

RESULTSDuring the Delta period, the BNT162b2 vaccine demonstrated an overall effectiveness 98.4% (95% CI, 98.1 to 98.7) against documented infection among adolescents, with no significant waning after receipt of the first dose. During the Omicron period, the overall effectiveness was estimated to be 74.3% (95% CI, 72.2 to 76.2) in preventing documented infection among children, which was higher against moderate or severe COVID-19 (75.5%; 95% CI, 69.0 to 81.0) and ICU admission with COVID-19 (84.9%; 95% CI, 64.8 to 93.5). In the adolescent population, the overall effectiveness against documented Omicron infection was 85.5% (95% CI, 83.8 to 87.1), with effectiveness of 84.8% (95% CI, 77.3 to 89.9) against moderate or severe COVID-19, and 91.5% (95% CI, 69.5 to 97.6) against ICU admission with COVID-19. The effectiveness of the BNT162b2 vaccine against the Omicron variant declined after 4 months following the first dose and then stabilized with higher levels of uncertainty. Across all three cohorts, the risk of cardiac outcomes was approximately 65% to 85% lower in the vaccinated group than that of the unvaccinated group accounting for possible misclassification bias.

CONCLUSIONSThis study suggests BNT162b2 was effective among children and adolescents in Delta and Omicron periods for a range of COVID-19-related outcomes and is associated with a lower risk for cardiac complications. Waning effectiveness over time suggests that revaccination may be needed in the future.</p>
      </div>
    </div>
  </div>
</div>









<script src="/TRxiv2/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://yorks0n.github.io/TRxiv2">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
